Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025

Rapport Therapeutics, Inc.

Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.
Phase 2a trial of RAP-219 in refractory focal epilepsy to report topline results in Q3 2025.
Phase 2a trial of RAP-219 in bipolar mania to initiate in Q3 2025 with data expected in H1 2027.
Sevigny brings 15+ years experience from Roche, Biogen, Novartis, and Merck to lead clinical strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.